<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561130</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT-Dapa</org_study_id>
    <nct_id>NCT02561130</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga</brief_title>
  <official_title>Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether in patients with early type 2 diabetes, a&#xD;
      short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin&#xD;
      glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving&#xD;
      sustained diabetes remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized controlled trial in 152 patients with&#xD;
      recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week&#xD;
      course of treatment with Forxiga, metformin, insulin glargine and lifestyle therapy, and (b)&#xD;
      standard diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all&#xD;
      participants with HbA1C&lt;7.3% at the 12 week visit, glucose-lowering medications will be&#xD;
      discontinued and participants will be encouraged to continue with lifestyle modifications and&#xD;
      regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience&#xD;
      hyperglycemia relapse after stopping drugs will receive standard glycemic management as&#xD;
      informed by the current Canadian Diabetes Association clinical practice guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Drug-free Diabetes Remission</measure>
    <time_frame>64 weeks after randomization</time_frame>
    <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Drug-free HbA1C &lt; 6.0%</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Drug-free complete diabetes remission is defined as HbA1C &lt; 6.0 % off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Diabetes Relapse Without Overt Hyperglycemia Off Diabetes Drugs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Diabetes relapse without overt hyperglycemia is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Hemoglobin (HbA1C)</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Expressed in Diabetes Control and Complications Trial (DCCT) units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-severe Symptomatic Hypoglycemic Episodes</measure>
    <time_frame>During 64 weeks of follow-up</time_frame>
    <description>Symptomatic hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Weight Loss From Baseline</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>(Weight at randomization - weight at 12 weeks)/(weight at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference From Baseline</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>(Waist circumference at 12 weeks - waist circumference at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Hypoglycemic Episodes</measure>
    <time_frame>During 64 weeks of follow-up</time_frame>
    <description>Severe hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following: (i) the event was associated with a documented self-measured or laboratory plasma glucose level &lt;/= 2.0 mmol/L or (ii) the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Dose is titrated to achieve fasting normoglycemia</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Dose is titrated to 1 g bid or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forxiga</intervention_name>
    <description>Dose is titrated to 10 mg po daily or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>dapagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle therapy</intervention_name>
    <description>Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>diet and exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. men and women 30-80 years of age inclusive;&#xD;
&#xD;
          2. type 2 diabetes mellitus diagnosed by a physician within 8 years prior to patient&#xD;
             enrollment;&#xD;
&#xD;
          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks&#xD;
             prior to screening and randomization;&#xD;
&#xD;
          4. HbA1C 6.5-9.5% inclusive on no hypoglycemic agents or HbA1C ≤ 8.0% on up to 2&#xD;
             glucose-lowering agents;&#xD;
&#xD;
          5. body mass index ≥ 23 kg/m2;&#xD;
&#xD;
          6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);&#xD;
&#xD;
          7. ability and willingness to self-inject insulin;&#xD;
&#xD;
          8. provision of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. current use of insulin therapy;&#xD;
&#xD;
          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;&#xD;
&#xD;
          3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR&lt;60&#xD;
             mL/min/1.73 m2 by MDRD formula;&#xD;
&#xD;
          4. history of lactic acidosis or diabetic ketoacidosis;&#xD;
&#xD;
          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper&#xD;
             limit of normal at the time of enrollment;&#xD;
&#xD;
          6. history of bladder cancer or undiagnosed hematuria;&#xD;
&#xD;
          7. history of breast cancer;&#xD;
&#xD;
          8. history of polycythemia;&#xD;
&#xD;
          9. evidence of volume depletion or hypotension (systolic blood pressure &lt; 90 mmHg);&#xD;
&#xD;
         10. systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 105 mmHg;&#xD;
&#xD;
         11. diagnosed cardiovascular disease (unless cleared for a moderate intensity exercise&#xD;
             program by a specialist) including:&#xD;
&#xD;
               1. any history of acute coronary syndrome, hospitalization for unstable angina,&#xD;
                  myocardial infarction, or revascularization with coronary artery bypass grafting&#xD;
                  or percutaneous coronary intervention;&#xD;
&#xD;
               2. other evidence of coronary artery disease;&#xD;
&#xD;
               3. peripheral vascular disease, valvular heart disease, cardiomyopathy, aortic&#xD;
                  dissection, tachyarrhythmias, bradyarrhythmias, prior stroke or TIA;&#xD;
&#xD;
               4. prior hospitalization for heart failure; or&#xD;
&#xD;
               5. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves,&#xD;
                  ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock,&#xD;
                  left bundle branch block, second or third degree atrioventricular block).&#xD;
&#xD;
         12. dependence on oxygen;&#xD;
&#xD;
         13. history of any disease requiring frequent intermittent or continuous systemic&#xD;
             glucocorticoid treatment;&#xD;
&#xD;
         14. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;&#xD;
&#xD;
         15. history of any major illness with a life expectancy of &lt; 3 years;&#xD;
&#xD;
         16. history of injury or any other condition that significantly limits participant's&#xD;
             ability to achieve moderate levels of physical activity;&#xD;
&#xD;
         17. any history of excessive alcohol intake, acute or chronic;&#xD;
&#xD;
         18. currently pregnant, or breastfeeding, or not using a reliable method of birth control&#xD;
             for the duration of the trial in all females with childbearing potential; reliable&#xD;
             methods of birth control include oral contraceptive (birth control pill), hormonal&#xD;
             injection, implant, patch, or vaginal ring, intrauterine device, barrier method&#xD;
             (condom and spermicide), tubal ligation, partner vasectomy or abstinence;&#xD;
&#xD;
         19. known hypersensitivity to metformin, Forxiga, or insulin glargine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia McInnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel C Gerstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michaels's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>November 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 24, 2020</results_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glargine</keyword>
  <keyword>Metformin</keyword>
  <keyword>Forxiga</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02561130/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="10.0"/>
                    <measurement group_id="B2" value="56.7" spread="9.6"/>
                    <measurement group_id="B3" value="56.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="26.7"/>
                    <measurement group_id="B2" value="35.8" spread="27.8"/>
                    <measurement group_id="B3" value="36.8" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin (HbA1C)</title>
          <description>Expressed in Diabetes Control and Complications Trial (DCCT) units</description>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="0.6"/>
                    <measurement group_id="B2" value="6.7" spread="0.7"/>
                    <measurement group_id="B3" value="6.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="5.8"/>
                    <measurement group_id="B2" value="32.5" spread="6.0"/>
                    <measurement group_id="B3" value="32.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group</title>
        <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
        <time_frame>24 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group</title>
          <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Drug-free Diabetes Remission</title>
        <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
        <time_frame>64 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Drug-free Diabetes Remission</title>
          <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Drug-free HbA1C &lt; 6.0%</title>
        <description>Drug-free complete diabetes remission is defined as HbA1C &lt; 6.0 % off glucose-lowering agents for at least 12 weeks.</description>
        <time_frame>24 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Drug-free HbA1C &lt; 6.0%</title>
          <description>Drug-free complete diabetes remission is defined as HbA1C &lt; 6.0 % off glucose-lowering agents for at least 12 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Diabetes Relapse Without Overt Hyperglycemia Off Diabetes Drugs</title>
        <description>Diabetes relapse without overt hyperglycemia is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Diabetes Relapse Without Overt Hyperglycemia Off Diabetes Drugs</title>
          <description>Diabetes relapse without overt hyperglycemia is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycated Hemoglobin (HbA1C)</title>
        <description>Expressed in Diabetes Control and Complications Trial (DCCT) units</description>
        <time_frame>12 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Glycated Hemoglobin (HbA1C)</title>
          <description>Expressed in Diabetes Control and Complications Trial (DCCT) units</description>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="0.4"/>
                    <measurement group_id="O2" value="6.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-severe Symptomatic Hypoglycemic Episodes</title>
        <description>Symptomatic hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia.</description>
        <time_frame>During 64 weeks of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-severe Symptomatic Hypoglycemic Episodes</title>
          <description>Symptomatic hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Weight Loss From Baseline</title>
        <description>(Weight at randomization - weight at 12 weeks)/(weight at randomization)</description>
        <time_frame>12 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Weight Loss From Baseline</title>
          <description>(Weight at randomization - weight at 12 weeks)/(weight at randomization)</description>
          <units>percentage of weight loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.2"/>
                    <measurement group_id="O2" value="1.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference From Baseline</title>
        <description>(Waist circumference at 12 weeks - waist circumference at randomization)</description>
        <time_frame>12 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference From Baseline</title>
          <description>(Waist circumference at 12 weeks - waist circumference at randomization)</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="4.1"/>
                    <measurement group_id="O2" value="-1.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Hypoglycemic Episodes</title>
        <description>Severe hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following: (i) the event was associated with a documented self-measured or laboratory plasma glucose level &lt;/= 2.0 mmol/L or (ii) the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
        <time_frame>During 64 weeks of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Hypoglycemic Episodes</title>
          <description>Severe hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following: (i) the event was associated with a documented self-measured or laboratory plasma glucose level &lt;/= 2.0 mmol/L or (ii) the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>64 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise&#xD;
insulin glargine: Dose is titrated to achieve fasting normoglycemia&#xD;
metformin: Dose is titrated to 1 g bid or maximal tolerated dose&#xD;
Forxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose&#xD;
Lifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Resection of liver metastases from colorectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genitourinary infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Other infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Abscess drainage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Moderate renal dysfunction defined as GFR 30-60 ml/min/1.73m2</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Natalia McInnes</name_or_title>
      <organization>McMaster University</organization>
      <phone>905-521-2100</phone>
      <email>natalia.mcinnes@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

